With the CytoPep project OntoChem tracks – in cooperation with Leipzig University – the development of targeted therapeutics against metastatic cancer diseases. Especially in case a primary tumor has metastasized, the prognoses for the patients becomes significantly worse. In such cases, systemic chemotherapies are without alternative. However, most chemotherapeutics cause sever side effects on healthy tissues as well.
To address this problem, OntoChem and Leipzig University develop smart therapeutics, consisting of highly potent cytotoxic/cytostatic agents and peptidic domains, which serve as tumor cell specific carrier. These conjugates should be able to selectively find and kill cancer cells, whereas normal cells should be spared.